Site Readiness Checklists for Clinical Trial Initiation Visits
Without a structured checklist, critical steps may be missed, such as:
Click to read the full article.
Site Management and Monitoring
Regulatory Reporting After Site Close-Out Visits in Clinical Trials
Post-COV regulatory reporting is a vital aspect of trial completion that ties together documentation, compliance, and site responsibilities. Properly executed reporting ensures the integrity of trial data, prevents compliance risks, and satisfies sponsor and regulatory obligations. CRAs, regulatory affairs, and investigators must work collaboratively to close the loop on site activities with thorough, timely, and accurate submissions. With a structured approach and adherence to GCP and SOPs, this final phase can be executed smoothly, paving the way for successful study close-out.
Click to read the full article.
Importance of GCP Training Prior to Site Activation in Clinical Trials
GCP is an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve human subjects. According to the EMA and USFDA, compliance with GCP ensures that rights, safety, and well-being of trial participants are protected and that trial data is credible and accurate.
Click to read the full article.
Archiving Essential Documents at the Site During Clinical Trial Close-Out
Essential documents are those which individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. As defined by ICH E6(R2), these documents demonstrate compliance with standards and allow for the reconstruction of study activities.
Click to read the full article.
Documenting SIV Outcomes and Action Items in Clinical Trials
Documentation serves as a verifiable record that the site was trained, equipped, and aligned with the expectations for trial conduct. It is a critical part of the Stability Studies and clinical trial quality framework.
Click to read the full article.
Final IP Reconciliation and Accountability in Clinical Trials
Final IP reconciliation is the process of comparing the amount of investigational product (IMP) received by the site, dispensed to trial subjects, returned (if applicable), destroyed, or otherwise accounted for, and identifying any discrepancies. This ensures that all IMPs are handled according to the protocol and regulatory guidelines before the site is officially closed.
Click to read the full article.
SIV Delays in Clinical Trials: Common Causes and Effective Solutions
SIV delays ripple across the clinical trial lifecycle:
Click to read the full article.
Site Readiness Criteria for Closure in Clinical Trials
Regulatory agencies expect sponsors to demonstrate that each investigative site was closed in a compliant, documented, and scientifically sound manner. For instance:
Click to read the full article.
Virtual Site Initiation Visits (SIVs): Best Practices and Tools
Virtual SIVs are remote meetings conducted using video conferencing tools to train investigative site personnel on the clinical trial protocol, sponsor expectations, investigational product (IP) handling, and Good Clinical Practice (GCP) compliance. They replicate all key components of traditional in-person SIVs—minus physical travel—through structured digital processes and documentation.
Click to read the full article.
Objectives of the Site Close-Out Visit (COV) in Clinical Trials
A Site Close-Out Visit is a formal monitoring visit conducted after the last patient completes the study and all required data has been collected, verified, and entered. The purpose is to ensure that the site has fulfilled all its obligations and that no outstanding issues remain related to patient safety, investigational product (IP) management, documentation, or data quality.
Click to read the full article.